RxDoctor Payments Data

Christopher Pucci, PA

Physician Assistant · Charlottesville, VANPI 1306463906

Payments from drug & device makers

$887in general payments, 2019–2025

Across 33 payments — averaging $26.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$178
  • Bayer$170
  • GSK$111
  • Neurocrine Biosciences, Inc.$94
  • Novo Nordisk$93
  • Alkermes, Inc.$45
  • plus $195 from 9 others

What the payments were for

  • Food & beverage$887100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$887 in reported general payments places this provider in the 70th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$2,298
Medicare patients
64
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin62$67,238
EliquisApixaban43$48,351
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$15,625
SymbicortBudesonide/Formoterol Fumarate13$4,866
Albuterol Sulfate HfaAlbuterol Sulfate59$2,690
Varenicline Tartrate12$2,107
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,060
Esomeprazole Magnesium12$1,906
Sertraline Hcl22$1,881
Atorvastatin Calcium147$1,275
Omeprazole108$988
Amlodipine Besylate152$815
Famotidine55$779
Metformin Hcl ErMetformin Hcl43$650
Duloxetine Hcl44$636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$48,35143 claims
GSKTrelegy Ellipta$111$15,62513 claims
AstraZenecaSymbicort$27$4,86613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →